Network meta-analysis suggests tirzepatide and surgery improve MASH resolution versus standard care in adults with obesity
Weight-loss drugs and surgery may clear fatty liver disease in adults with high BMI
This systematic review and network meta-analysis evaluates interventions for metabolic dysfunction-associated steatotic liver disease and st…
A new analysis suggests tirzepatide, semaglutide, and surgery might help resolve fatty liver disease without worsening scarring in adults wi…
Essential phospholipids reduced hepatic steatosis and improved HbA1c in patients with MASLD and type 2 diabetes over 6 months.
Essential Phospholipids Reduce Liver Fat In Six Months
This randomised, placebo-controlled phase 4 trial enrolled 193 patients with metabolic dysfunction-associated steatotic liver disease and ty…
Essential phospholipids may lower liver fat and improve energy levels for people with fatty liver disease and diabetes within just six month…
Systematic review and meta-analysis evaluates ML and DL models for diagnosing MASH and fibrosis
AI models help doctors spot liver disease with high accuracy
This systematic review and meta-analysis of 106 studies assessed machine learning (ML) and deep learning (DL) models for diagnosing metaboli…
New computer tools can diagnose fatty liver disease and scarring with impressive accuracy. This review analyzed data from many studies to se…
Systematic review finds weak link between atypical antipsychotics and MASLD in youth
Atypical antipsychotics show a small link to liver disease in young patients
This systematic review and meta-analysis of 3 studies examined the association between atypical antipsychotics and metabolic dysfunction-ass…
A review of three studies found a small link between atypical antipsychotics and liver disease in children, but the evidence is limited.
Plasma homocysteine levels associated with increased risk of incident metabolic dysfunction-associated steatotic liver disease
High or low homocysteine levels raise your liver disease risk
This cohort study included 5,184 adults from the Dalian Health Management Cohort. Researchers found a positive association between plasma ho…
Both very high and very low homocysteine levels could increase your risk of developing fatty liver disease in the future.
Narrative review of phytochemicals in zebrafish models for metabolic dysfunction-associated steatotic liver disease and related conditions
Tiny fish help find new safe liver disease drugs
This narrative review examines preclinical data on phytochemicals using zebrafish models for metabolic dysfunction-associated steatotic live…
Tiny zebrafish are helping scientists test plant-based medicines for liver disease faster than ever before while checking safety and toxicit…
Systematic review finds gut microbiota drugs reduce liver enzymes in MASLD patients compared to placebo.
New drugs targeting gut bacteria may finally treat fatty liver disease
This systematic review and network meta-analysis evaluated gut microbiota-regulating drugs, including probiotics, prebiotics, synbiotics, an…
New medicines that change gut bacteria lower liver enzymes in fatty liver patients, offering hope for those struggling with diet and exercis…
High aMAP Risk Scores Associated With Increased Mortality in Metabolic and Alcohol-Related Liver Disease
New Score Predicts Liver Disease Death Risk Across All Types
This cohort study analyzed 32,654 NHANES participants and 642 from a Southern Chinese cohort to evaluate the aMAP risk score. High aMAP scor…
A new blood test score helps doctors spot patients with fatty liver disease who face a higher risk of dying soon.
Higher ZJU index associated with worse metabolic profiles in adults with type 2 diabetes and hyperuricemia
</think>
This retrospective cross-sectional analysis of 1772 adults with type 2 diabetes mellitus evaluated the association between the Zhejiang Univ…
A simple calculation used for liver health may also warn about uric acid problems in diabetes.
Pathophysiological review explores platelet activity and antiplatelet agents in metabolic dysfunction-associated steatohepatitis and steatotic liver disease.
New Role for Blood Cells in Fatty Liver Disease Could Change Treatment
This pathophysiological review examines the role of platelet activity and antiplatelet agents in metabolic dysfunction-associated steatohepa…
Understanding how blood cells affect your liver could lead to new, targeted treatments for a dangerous liver condition.
Transcriptomic signature distinguishes MASL from MASH using neural network model
New Blood Test Could Spot Hidden Liver Damage Before It’s Too Late
This observational study combined transcriptomic and single-cell analysis with an artificial neural network to differentiate metabolic dysfu…
This research could finally give doctors a simple blood test to tell the difference between harmless fat buildup and dangerous liver scarrin…
Non-traditional lipid indices associate with coronary heart disease risk in MASLD and type 2 diabetes patients.
This blood fat test may spot heart disease risk in diabetics better than standard cholesterol checks
This multicenter retrospective cohort study included 1,823 patients with comorbid metabolic dysfunction-associated steatotic liver disease a…
For people with diabetes and fatty liver, a new set of blood fat numbers could reveal heart risks that standard cholesterol tests often miss…